---
layout: default
title: Ranolazine
parent: 僅模型預測 (L5)
nav_order: 295
evidence_level: L5
indication_count: 1
---

# Ranolazine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ranolazine: From Unspecified Original Indication to Nephrogenic Syndrome of Inappropriate Antidiuresis

## One-Sentence Summary

> Ranolazine's original indication and mechanism of action are not available in the current evidence pack.
> The TxGNN model predicts it may be effective for **Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD)**,
> with **0 clinical trials** and **0 publications** currently supporting this direction — this is a pure computational prediction with no mechanistic or clinical corroboration.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no approved indication on record (drug not marketed in Norway) |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data for ranolazine is not available in the source database. As a result, no molecular pathway connecting ranolazine to the pathophysiology of NSIAD — which is driven by gain-of-function mutations in the AVPR2 gene and dysregulated activation of renal collecting-duct water channels — can be established or verified.

Because the drug's original indication is also unrecorded in this evidence pack, no relationship between an original indication and NSIAD can be assessed. This candidate rank (score 0.996) is derived solely from TxGNN knowledge-graph embedding similarity, without any explainable biological pathway. The possibility that this represents graph noise or a spurious association (e.g., arising from shared drug-class or side-effect nodes rather than a true therapeutic mechanism) cannot be excluded.

Given the absence of MOA, clinical, and literature support, this prediction should currently be treated as a hypothesis-generating signal only, not as a basis for further development action.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Norway Market Information

No marketing authorizations on record — ranolazine is not currently marketed in Norway (0 licenses).

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate is supported only by a TxGNN embedding-similarity score (L5, S0 decision stage), with no mechanistic rationale, no clinical trials, no literature, and no regulatory/safety data available. There is no basis at this time to advance beyond model prediction.

**To proceed, the following is needed:**
- Ranolazine mechanism of action (MOA) data (DrugBank API or equivalent source)
- Original approved indication(s) for ranolazine, to assess biological plausibility relative to NSIAD
- TFDA/regulatory label warnings and contraindications (currently blocking S1 safety screening)
- Any preclinical or case-level evidence linking ranolazine to vasopressin/AVPR2 pathway activity
- Confirmation of whether this prediction is corroborated in other markets' evidence packs (if available), to rule out a graph-noise artifact
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

